Search

Displaying results 5071 - 5080 of 9706 in total
  1. Drug

    Hexoprenaline

    go.drugbank.com/drugs/DB08957
    ApprovedWithdrawn

    Hexoprenaline is a stimulant of beta 2 adrenergic receptors. It is used as a bronchodilator, antiasthmatic, and tocolytic agent.

  2. Drug

    Etofenamate

    go.drugbank.com/drugs/DB08984
    Investigational

    It is a non-steroidal anti-inflammatory drug (NSAID).

    Products: SOLUCION AL 50% / 2ML
  3. Drug

    Etidocaine

    go.drugbank.com/drugs/DB08987
    Approved

    Etidocaine has a long duration of activity, but has the main disadvantage of increased bleeding during oral surgery.

  4. Drug

    Eprazinone

    go.drugbank.com/drugs/DB08990
    ApprovedWithdrawn

    Eprazinone (trade name Eftapan) is a mucolytic drug, and relieves bronchospasms.

  5. Drug

    Benzoctamine

    go.drugbank.com/drugs/DB09021
    Experimental

    Benzoctamine is a drug with two main uses. It can be used as a sedative which does not depress the respiratory system, but rather stimulates it.

  6. Drug

    Naloxegol

    go.drugbank.com/drugs/DB09049
    ApprovedInvestigational

    Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca.

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Olaparib

    go.drugbank.com/drugs/DB09074
    ApprovedInvestigational

    [L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell … Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  8. Drug

    Nintedanib

    go.drugbank.com/drugs/DB09079
    ApprovedInvestigational

    Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC). … [A185237] As a chemotherapeutic agent for NSCLC, nintedanib, in combination with [Docetaxel], is reserved for patients who have tried and failed first-line chemotherapeutic options.[L8459]

  9. Drug

    Olodaterol

    go.drugbank.com/drugs/DB09080
    ApprovedInvestigational

    A once-a-day treatment with a LABA has several advantages over short-acting bronchodilators and twice-daily LABAs including improved convenience and compliance and improved airflow over a 24-hour period … Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, via a downstream L-type calcium channel interaction, mediates smooth muscle

  10. Drug

    Ivabradine

    go.drugbank.com/drugs/DB09083
    ApprovedInvestigational

    Ivabradine acts by selectively inhibiting the "funny" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the … Therefore, as ivabradine is designed as a "pure" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing

    Products: IVABRADIN AL 5MG, IVABRADIN AL 7.5MG